In Vitro Antimicrobial Activity of Razupenem (SMP-601, PTZ601) against Anaerobic Bacteria | Zendy

Chau Minh Tran | Zendy; Kaori Tanaka | Zendy; Yuka Yamagishi | Zendy; Takatsugu Goto | Zendy; Hiroshige Mikamo | Zendy; Kunitomo Watanabe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Antimicrobial Activity of Razupenem (SMP-601, PTZ601) against Anaerobic Bacteria

Author(s) -

Chau Minh Tran,

Kaori Tanaka,

Yuka Yamagishi,

Takatsugu Goto,

Hiroshige Mikamo,

Kunitomo Watanabe

Publication year - 2011

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01038-10

Subject(s) - bacteroides fragilis , microbiology and biotechnology , prevotella , meropenem , anaerobic bacteria , bacteroides , fusobacterium , carbapenem , antimicrobial , biology , doripenem , bacteria , antibiotics , antibiotic resistance , genetics

We evaluated the in vitro antianaerobic activity of razupenem (SMP-601, PTZ601), a new parenterally administered carbapenem, against 70 reference strains and 323 clinical isolates. Razupenem exhibited broad-spectrum activity against anaerobes, inhibiting most of the reference strains when used at a concentration of ≤1 μg/ml. Furthermore, it exhibited strong activity, comparable to those of other carbapenems (meropenem and doripenem), against clinically isolated non-fragilis Bacteroides spp. (MIC90s of 2 μg/ml), with MIC90 values of 0.06, 0.03, and 0.5 μg/ml against Prevotella spp., Porphyromonas spp., and Fusobacterium spp., respectively. Clinical isolates of anaerobic Gram-positive cocci, Eggerthella spp., and Clostridium spp. were highly susceptible to razupenem (MIC90s, 0.03 to 1 μg/ml).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research